Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial

14 Aug 2019

Abstract excerpt

Human interleukin-12 (hIL-12) is a cytokine with anticancer activity, but its systemic application is limited by toxic inflammatory responses. We assessed the safety and biological effects of an hIL-12 gene, transcriptionally regulated by an oral activator. A multicenter phase 1 dose-escalation trial (NCT02026271) treated 31 patients undergoing resection of recurrent high-grade glioma. Resection cavity walls were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Glioma Diagnosis and Treatment
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31413142
DOI: 10.1126/scitranslmed.aaw5680

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trialPMID 31413142Read ↗

Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.Semantic proximity Read ↗

In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiformeSemantic proximity Read ↗

Intratumoral gene delivery of 4-1BBL boosts IL-12-triggered anti-glioblastoma immunitySemantic proximity Read ↗

Optimization of the Tet-on System To Regulate Interleukin 12 Expression in the Liver for the Treatment of Hepatic TumorsSemantic proximity Read ↗

A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injectionSemantic proximity Read ↗

Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: Results of a first-in-human Phase 1 trialSemantic proximity Read ↗

Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trialSemantic proximity Read ↗

Gene Therapy of Cancer Based on Interleukin 12Semantic proximity Read ↗

Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.Semantic proximity Read ↗

IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine gliomaSemantic proximity Read ↗

Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.Semantic proximity Read ↗

Convection-enhanced Delivery of Interleukin-13 Receptor-directed Cytotoxin for Malignant Glioma Therapy*Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.